DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer.
|
Shape Divider - Style triangle
OUR TECHNOLOGYDepYmed is developing novel therapeutics targeting the role of protein tyrosine phosphatases in signaling pathways involved in the pathology of multiple diseases.
Advancing two orally bioavailable small molecules into clinical trials for: We are building a library of novel selective PTP1B (phosphatase) inhibitors with therapeutic potential for other major metabolic, inflammatory and neurodegenerative diseases. |
Shape Divider - Style triangle
Shape Divider - Style triangle
RECENT NEWS
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | May 31, 2023 DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
By DepYmed, Inc. | November 16, 2022 DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease
By DepYmed, Inc. | May 23, 2022 DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
By DepYmed, Inc. | May 3, 2022 Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer
By DepYmed, Inc. | March 10, 2022 |
Shape Divider - Style triangle